In aspects, a cannabis extract enriched in polyphenolic compounds is provided herein. Also provided herein is a method for enriching a composition with polyphenolic compounds as well as compositions made by the method. Various cosmetic and pharmaceutical products, methods, and uses are provided herein as well as natural health products.

The invention provides separation media of substantially monodisperse populations of substantially spherical particles of polyarylketone polymers or of thio-analogues of such polymers, of selected sizes, and further provides containers, such as chromatographic columns and cartridges, containing substantially monodisperse populations of such particles.

The invention provides separation media of substantially monodisperse populations of substantially spherical particles of polyarylketone polymers or of thio-analogues of such polymers, of selected sizes, and further provides containers, such as chromatographic columns and cartridges, containing substantially monodisperse populations of such particles.

The present invention provides novel chromatographic materials, e.g., for chromatographic separations, processes for its preparation and separations devices containing the chromatographic material; separations devices, chromatographic columns and kits comprising the same; and methods for the preparation thereof. The chromatographic materials of the invention are chromatographic materials comprising having a narrow particle size distribution.

The present invention provides novel chromatographic materials, e.g., for chromatographic separations, processes for its preparation and separations devices containing the chromatographic material; separations devices, chromatographic columns and kits comprising the same; and methods for the preparation thereof. The chromatographic materials of the invention are chromatographic materials comprising having a narrow particle size distribution.

The invention relates to a method for preparation of a sample (10) of a formulation (11) for subsequent endotoxin determination, the formulation (11) suspected of comprising an endotoxin, the formulation (11) preferentially being a pharmaceutical formulation. The method comprises the following steps: application of the sample (10) to an endotoxin-free centrifugation column (2) containing a size exclusion chromatography matrix (5) that has been equilibrated with a suitable equilibration buffer (6) and elution of a flow through (15) of the sample by centrifugation, which flow through (15) can then be used for endotoxin determination. The equilibration buffer (6) is selected according to a subsequently used method of endotoxin determination, the equilibration buffer (6) only containing components not interfering with subsequently used method of endotoxin determination. Furthermore, the invention relates to a kit (20) for preparation of a sample (10).

A porous polymer monolith comprises a polymer body having macroporous through-pores that facilitate fluid flow through the body and an array of mesopores adapted to bind from the fluid flow molecules of a predetermined range of sizes, wherein the surface area of the monolith is predominantly provided by the mesopores. Also disclosed is a method of making a porous polymer monolith. The method includes forming a polymer body by phase separation out of a solution containing at least a monomer, a crosslinker and a primary porogen, whereby the body contains multiple macroporous through-pores, wherein the solution further contains a secondary porogen comprising oligomers inert with respect to the monomer and cross-linker but chemically compatible with the monomer so as to form mesostructures within the polymer body during said phase separation, and washing the mesostructures from the body to provide an array of mesopores such that the surface area of the monolith is predominantly provided by the mesopores.

A porous polymer monolith comprises a polymer body having macroporous through-pores that facilitate fluid flow through the body and an array of mesopores adapted to bind from the fluid flow molecules of a predetermined range of sizes, wherein the surface area of the monolith is predominantly provided by the mesopores. Also disclosed is a method of making a porous polymer monolith. The method includes forming a polymer body by phase separation out of a solution containing at least a monomer, a crosslinker and a primary porogen, whereby the body contains multiple macroporous through-pores, wherein the solution further contains a secondary porogen comprising oligomers inert with respect to the monomer and cross-linker but chemically compatible with the monomer so as to form mesostructures within the polymer body during said phase separation, and washing the mesostructures from the body to provide an array of mesopores such that the surface area of the monolith is predominantly provided by the mesopores.

A zearalenone functionalized graphene surface molecularly imprinted material, a preparation method therefor and the use thereof, which belong to the technical field of molecularly imprinted materials. The zearalenone functionalized graphene surface molecularly imprinted material is prepared by using RGO as a carrier, CDHB as a template molecule, 1-ALPP as a functional monomer, TRIM as a cross-linking agent, AIBN as an initiator, and acetonitrile as a pore-forming agent.

The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIF) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.